Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Comment by DavidKingCanadaon Jul 05, 2021 12:47pm
118 Views
Post# 33493155

RE:RE:RE:RE:RE:RE:RE:Share Price vs Market Cap

RE:RE:RE:RE:RE:RE:RE:Share Price vs Market CapTB, you are correct as this is not my Day Job. I manage a Transportation Company and are also involved in the day to day Finances. Every Day Trader bought Calls for Biogen before and after Aducanumab was Approved. Congrats on your $750.00 Profit. And guess what, if you bought Puts instead or Shorted you would have been better off. Anyone can look up the Numbers and see for themselves.I don't Day Trade as its not my Job and I would much rather Invest in Companies Long Term. 

Not too sure why some members on this Message Board are always on edge and bashing everyone in sight for some very basic questions and if TB claims to always have inside information then please share with us otherwise stop misleading Investors by claiming to do so. A quick Comment History Search reveals quite a bit about TB and his/her true intentions. Let's keep the peace shall we! Cheers! 
<< Previous
Bullboard Posts
Next >>